Tin tức & Cập nhật

A study presented at ASCO GI 2026 shows that colorectal cancer (CRC) survivors who remain physically active, particularly through walking, are less likely to experience severe fatigue and more likely to report better quality of life (QoL).

In the phase III COMMIT* trial, a combination of mFOLFOX6 (FFX), atezolizumab, and bevacizumab significantly improves progression-free survival (PFS) in patients with deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC).